| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
| Targets |
1-Hydroxypyrene targets the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that mediates the toxic effects of environmental pollutants. As an AhR agonist, it can activate AhR signaling, which may contribute to renal fibrosis. It has also been shown to inhibit DNA polymerase, RNA polymerase, and protein synthesis in vitro, and to inhibit mitochondrial dehydrogenases, leading to a decrease in cellular energy production.
|
|---|---|
| ln Vitro |
1-Hydroxypyrene exhibits in vitro activity as a biomarker of PAH exposure and as an AhR agonist. It inhibits DNA polymerase, RNA polymerase, and protein synthesis in vitro. It also inhibits mitochondrial dehydrogenases, leading to a decrease in cellular energy production. Its activity in the ER agonist pathway has been noted. These in vitro activities confirm its utility as a research tool for studying PAH toxicity and AhR signaling.
|
| ln Vivo |
In vivo, 1-hydroxypyrene is primarily used as a biomarker for PAH exposure. It is excreted in urine and can be used as an analytical marker for exposure to pyrene. Urinary 1-hydroxypyrene is extensively used in occupational health studies to monitor PAH exposure. Its presence in urine reflects recent exposure to PAHs, making it a valuable tool for environmental and occupational health research.
|
| Enzyme Assay |
In vitro assays for 1-hydroxypyrene are analytical rather than biological. The compound is measured in urine and other biological samples using high-performance liquid chromatography (HPLC) with fluorescence detection or liquid chromatography-mass spectrometry (LC-MS). Its levels are quantified to assess human exposure to PAHs. AhR activation can be assessed using reporter gene assays in cell lines expressing AhR.
|
| Cell Assay |
Cellular assays for 1-hydroxypyrene are used to study its effects on AhR signaling and cellular metabolism. Cells are treated with the compound, and AhR target gene expression (e.g., CYP1A1) is measured by qPCR. Mitochondrial function is assessed by measuring oxygen consumption or ATP production. Cytotoxicity assays can be performed to assess its effects on cell viability.
|
| Animal Protocol |
In vivo animal experiments with 1-hydroxypyrene are primarily conducted for toxicological and biomarker studies. The compound is administered to animals, and its levels in urine and tissues are measured to validate its use as a biomarker for PAH exposure. Its effects on AhR signaling and renal function can be studied in animal models of PAH toxicity.
|
| ADME/Pharmacokinetics |
1-Hydroxypyrene is a small, lipophilic molecule with a molecular weight of 218.25 and a molecular formula of C16H10O. It is excreted in urine as a metabolite of pyrene. Its pharmacokinetic properties are related to its role as a PAH metabolite; it is formed in the liver and excreted in urine. The compound is typically stored at room temperature.
|
| Toxicity/Toxicokinetics |
1-Hydroxypyrene is considered a biomarker of PAH exposure and is not typically evaluated for toxicity as a compound itself. However, as an AhR agonist, it may contribute to PAH-associated toxicities such as renal fibrosis. The compound is intended for research and analytical applications only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
1-Hydroxypyrene is a member of the pyrene class of compounds.
1-Hydroxypyrene is a monohydroxylated metabolite of pyrene and the most validated biomarker for assessing human exposure to polycyclic aromatic hydrocarbons (PAHs). It is analyzed in urine samples as the major biomarker of exposure to pyrenes. It functions as an orally active AhR agonist and has been shown to inhibit DNA and RNA polymerases and mitochondrial dehydrogenases in vitro. |
| Molecular Formula |
C₁₆H₁₀O
|
|---|---|
| Molecular Weight |
218.26
|
| Exact Mass |
218.073
|
| CAS # |
5315-79-7
|
| PubChem CID |
21387
|
| Appearance |
Light yellow to light brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
437.4±14.0 °C at 760 mmHg
|
| Melting Point |
179-182ºC(lit.)
|
| Flash Point |
213.0±12.0 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.895
|
| LogP |
4.43
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
300
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BIJNHUAPTJVVNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H10O/c17-14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9,17H
|
| Chemical Name |
pyren-1-ol
|
| Synonyms |
1Hydroxypyrene; 1 Hydroxypyrene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~229.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5817 mL | 22.9085 mL | 45.8169 mL | |
| 5 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL | |
| 10 mM | 0.4582 mL | 2.2908 mL | 4.5817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
